

Table S1 Search strategy	
Database	Search statement
PubMed	
1	"Lung Neoplasms"[Mesh] OR "Carcinoma, Non-Small-Cell Lung"[Mesh]
2	lung cancer
3	1 or 2
4	((((((((((Angiogenesis Inhibitors) OR (multitargeted tyrosine kinase inhibitors)) OR (multi-targeted tyrosine kinase inhibitors))) OR (anlotinib)) OR (apatinib)) OR (fruquintinib)) OR (sorafenib)) OR (lenvatinib)) OR (lenvatinib)) OR (cediranib)) OR (vandetanib)) OR (vandetanib)) OR (nintedanib)) OR (pazopanib)) OR (axitinib)
5	immune Checkpoint Inhibitors[MeSH Terms]
6	((((((((((((((((((Immune Checkpoint Inhibitor*) OR (Checkpoint Inhibitors, Immune)) OR (Immune Checkpoint Inhibitor)) OR (Checkpoint Inhibitor, Immune)) OR (Checkpoint Inhibitor, Immune)) OR (Checkpoint Blockers, Immune)) OR (Immune Checkpoint Blockade)) OR (Checkpoint Blockade, Immune)) OR (Immune Checkpoint Inhibition)) OR (Checkpoint Inhibition, Immune)) OR (PD-L1 Inhibitor*)) OR (Programmed Death-Ligand 1 Inhibitor*)) OR (PD-1-PD-L1 Blockade)) OR (PD-1-PD-L1 Blockade)) OR (PD-1-PD-L1 Blockade)) OR (CTLA-4 Inhibitor*)) OR (CTLA?4 Inhibitors or Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor*)) OR (PD-1 Inhibitor*)) OR (Programmed Cell Death Protein 1 Inhibitor*)) OR (Sugemalimab)) OR (Nivolumab)) OR (Pembrolizumab)) OR (Tislelizumab)) OR (Sintilimab)) OR (Camrelizumab)) OR (Toripalimab)) OR (Atezolizumab)) OR (Durvalumab)) OR (Avelumab)
7	5 or 6
8	3 and 4 and 7
9	8 Filters: Humans
Medline	
1	lung cancer.mp. or exp Lung Neoplasms
2	Carcinoma, Non-Small-Cell Lung/ or lung carcinoma.mp.
3	pulmonary carcinoma.mp.
4	1 or 2 or 3
5	exp Angiogenesis Inhibitors/ or multitargeted tyrosine kinase inhibitors.mp.
6	(anlotinib or apatinib or fruquintinib or sorafenib or lenvatinib or lenvatinib or cediranib or vandetanib or vandetanib or nintedanib or pazopanib or axitinib).af.
7	multi-targeted tyrosine kinase inhibitors.mp.
8	5 or 6 or 7
9	immune Checkpoint Inhibitors.mp. or exp Immune Checkpoint Inhibitors/ or exp Immunotherapy
10	(Immune Checkpoint Inhibitor* or Checkpoint Inhibitors, Immune or Immune Checkpoint Inhibitor or Checkpoint Inhibitor, Immune or Checkpoint Inhibitor, Immune or Checkpoint Blockers, Immune or Immune Checkpoint Blockade or Checkpoint Blockade, Immune or Immune Checkpoint Inhibition or Checkpoint Inhibition, Immune or PD-L1 Inhibitor* or Programmed Death-Ligand 1 Inhibitor* or PD-1-PD-L1 Blockade or PD-1-PD-L1 Blockade or PD-1-PD-L1 Blockade or CTLA-4 Inhibitor* or CTLA?4 Inhibitors or Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor* or PD-1 Inhibitor* or Programmed Cell Death Protein 1 Inhibitor* or Sugemalimab or Nivolumab or Pembrolizumab or Tislelizumab or Sintilimab or Camrelizumab or Toripalimab or Atezolizumab or Durvalumab or Avelumab).af.
11	9 or 10
12	4 and 8 and 11
13	limit 12 to humans
EMBASE	
1	lung cancer.mp. or exp lung cancer
2	lung carcinoma.mp. or exp lung carcinoma
3	pulmonary carcinoma.mp.
4	1 or 2 or 3
5	multitargeted tyrosine kinase inhibitors.mp.
6	(anlotinib or apatinib or fruquintinib or sorafenib or lenvatinib or lenvatinib or cediranib or vandetanib or vandetanib or nintedanib or pazopanib or axitinib).af.
7	multi-target tyrosine kinase inhibitors.mp.
8	5 or 6 or 7
9	immune Checkpoint Inhibitors.mp. or exp immune checkpoint inhibitor
10	(Immune Checkpoint Inhibitor* or Checkpoint Inhibitors, Immune or Immune Checkpoint Inhibitor or Checkpoint Inhibitor, Immune or Checkpoint Inhibitor, Immune or Checkpoint Blockers, Immune or Immune Checkpoint Blockade or Checkpoint Blockade, Immune or Immune Checkpoint Inhibition or Checkpoint Inhibition, Immune or PD-L1 Inhibitor* or Programmed Death-Ligand 1 Inhibitor* or PD-1-PD-L1 Blockade or PD-1-PD-L1 Blockade or PD-1-PD-L1 Blockade or CTLA-4 Inhibitor* or CTLA?4 Inhibitors or Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor* or PD-1 Inhibitor* or Programmed Cell Death Protein 1 Inhibitor* or Sugemalimab or Nivolumab or Pembrolizumab or Tislelizumab or Sintilimab or Camrelizumab or Toripalimab or Atezolizumab or Durvalumab or Avelumab).af.
11	9 or 10
12	4 and 8 and 11
13	limit 12 to human
Clinical trial	
1	Condition: Lung cancer or lung neoplasms
2	Intervention: anlotinib or apatinib or fruquintinib or sorafenib or lenvatinib or cediranib or vandetanib or nintedanib or pazopanib or axitinib